Cloudbreak Pharma Inc. (SEHK: 2592)
Health Care · Biotechnology · US
HK$1.18
-3.69% today · -78.0% 1Y
Cloudbreak Pharma Inc. (SEHK: 2592) operates in the Biotechnology industry within the Health Care sector. The company is valued at $126.46M and employs 61 people.
Over the last twelve months the share price has lost 78.0%, trading between 0.90 and 9.58.
Tweenvest scores Cloudbreak Pharma Inc. across four factors: quality 28/100, value 31/100. Its strongest factor is value.
2592 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $126.46M
- Revenue (TTM)
- $253.00K
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$9.58
- 52-week low
- HK$0.90
- Avg volume (3M)
- —
- Shares outstanding
- 844.57M
- Employees
- 61
- Next earnings
- —
About Cloudbreak Pharma Inc.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
- ISIN
- KYG2215S1084
- Founded
- 2015
- Listed since
- Jul 2, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.